Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 9/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.63 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.63 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | DRD1 | P21728 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29938908 | 1.00 | FTO (1.00) | FTOMAPTMEN1HTTKMT2A | |
| SCHEMBL9626406 | 0.89 | FTO (0.81) | FTOMAPTMEN1HTTKMT2A | |
| SCHEMBL31676645 | 0.89 | FTO (0.80) | FTOMAPTMEN1HTTKMT2A | |
| SCHEMBL12500117 | 0.89 | FTO (0.80) | FTOMAPTMEN1HTTKMT2A | |
| SCHEMBL14213150 | 0.88 | FTO (0.79) | FTOMAPTMEN1HTTKMT2A | |
| SCHEMBL4600340 | 0.88 | FTO (0.79) | FTOMAPTMEN1HTTKMT2A | |
| SCHEMBL29406840 | 0.87 | FTO (0.78) | FTOMAPTMEN1HTTKMT2A | |
| SCHEMBL25103 | 0.87 | FTO (0.78) | FTOMAPTMEN1HTTKMT2A | |
| SCHEMBL10400640 | 0.87 | FTO (0.77) | FTOMAPTMEN1HTTKMT2A | |
| SCHEMBL12693566 | 0.86 | FTO (0.76) | FTOMAPTMEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118027054-A | Preparation process of high-purity 5-amide fluorescein | 浙江鑫科医疗科技有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20230135347-A1 | HYDROGELS WITH BIODEGRADABLE CROSSLINKING | PROLYNX LLC (US) | 2023-05-04 | — | — | US | disclosed |
| US-11181803-B2 | Hydrogels with biodegradable crosslinking | PROLYNX LLC (US) | 2021-11-23 | — | — | US | disclosed |
| US-11179470-B2 | Hydrogels with biodegradable crosslinking | PROLYNX LLC (US) | 2021-11-23 | — | — | US | disclosed |
| US-11124522-B2 | Chemosensor and a method of detecting palladium ions | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2021-09-21 | — | — | US | disclosed |
| US-20200392148-A1 | CHEMOSENSOR AND A METHOD OF DETECTING PALLADIUM IONS | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2020-12-17 | — | — | US | disclosed |
| US-20200054756-A1 | HYDROGELS WITH BIODEGRADABLE CROSSLINKING | PROLYNX LLC (US) | 2020-02-20 | — | — | US | disclosed |
| US-10398779-B2 | Hydrogels with biodegradable crosslinking | PROLYNX LLC (US) | 2019-09-03 | — | — | US | disclosed |
| US-20190209691-A1 | HYDROGELS WITH BIODEGRADABLE CROSSLINKING | PROLYNX LLC (US) | 2019-07-11 | — | — | US | disclosed |
| US-20190209692-A1 | HYDROGELS WITH BIODEGRADABLE CROSSLINKING | PROLYNX LLC (US) | 2019-07-11 | — | — | US | disclosed |
| EP-2414828-A1 | METHODS FOR TESTING LIGAND BINDING TO G PROTEIN-COUPLED RECEPTORS | GE Healthcare UK Limited (GB) | 2012-02-08 | — | — | EP | disclosed |
| EP-2359140-A1 | METHODS FOR TESTING BINDING OF A LIGAND TO A G PROTEIN-COUPLED RECEPTOR | GE Healthcare UK Limited (GB) | 2011-08-24 | — | — | EP | disclosed |
| EP-2329268-A1 | METHODS AND COMPOUNDS FOR TESTING BINDING OF A LIGAND TO A G PROTEIN-COUPLED RECEPTOR | GE Healthcare UK Limited (GB) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010112417-A1 | METHODS FOR TESTING LIGAND BINDING TO G PROTEIN-COUPLED RECEPTORS | GE HEALTHCARE UK LIMITED (GB) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010063832-A1 | METHODS FOR TESTING BINDING OF A LIGAND TO A G PROTEIN-COUPLED RECEPTOR | GE HEALTHCARE UK LIMITED (GB) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010037718-A1 | METHODS AND COMPOUNDS FOR TESTING BINDING OF A LIGAND TO A G PROTEIN-COUPLED RECEPTOR | GE HEALTHCARE UK LIMITED (GB) | 2010-04-08 | — | — | WO | disclosed |
| US-6229055-B1 | SYNTHESIS OF FLUORINATED RESORCINOL WHICH IS USEFUL IN THE PREPARATION OF FLUORINATED FLUORESCEIN AND RHODOL DYES SUITABLE FOR USE AS TRACERS, LABELS, OR INTERMEDIATES | MOLECULAR PROBES, INC. | 2001-05-08 | — | — | US | disclosed |
| US-6162931-A | Fluorinated xanthene derivatives | MOLECULAR PROBES, INC. (US) | 2000-12-19 | — | — | US | disclosed |
| US-4894348-A | IMMUNOASSAYS | SCLAVO INC., WAYNE, NJ A CORP. OF DE | 1990-01-16 | — | — | US | disclosed |
| WO-1989000291-A1 | FLUORESCEIN-CONJUGATED PROTEINS WITH ENHANCED FLUORESCENCE | SCLAVO INC., WEST COAST (US) | 1989-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11124522-B2 | Chemosensor and a method of detecting palladium ions | DDT, PDCD1, PDCD10 | FTO 766/4885MAPT 2523/4885MEN1 3564/4885 |
| US-20200392148-A1 | CHEMOSENSOR AND A METHOD OF DETECTING PALLADIUM IONS | DDT, PDCD1, PDCD10 | FTO 766/4885MAPT 2523/4885MEN1 3564/4885 |
| US-10398779-B2 | Hydrogels with biodegradable crosslinking | IDUA, APEH, GUSB | FTO 3442/4885MAPT 3269/4885MEN1 2686/4885 |
| US-20230135347-A1 | HYDROGELS WITH BIODEGRADABLE CROSSLINKING | IDUA, APEH, GUSB | FTO 3442/4885MAPT 3269/4885MEN1 2686/4885 |
| US-20200054756-A1 | HYDROGELS WITH BIODEGRADABLE CROSSLINKING | IDUA, APEH, GUSB | FTO 3442/4885MAPT 3269/4885MEN1 2686/4885 |
| US-11179470-B2 | Hydrogels with biodegradable crosslinking | IDUA, APEH, GUSB | FTO 3442/4885MAPT 3269/4885MEN1 2686/4885 |
| US-20190209691-A1 | HYDROGELS WITH BIODEGRADABLE CROSSLINKING | IDUA, APEH, GUSB | FTO 3442/4885MAPT 3269/4885MEN1 2686/4885 |
| US-20190209692-A1 | HYDROGELS WITH BIODEGRADABLE CROSSLINKING | IDUA, APEH, GUSB | FTO 3442/4885MAPT 3269/4885MEN1 2686/4885 |
| US-11181803-B2 | Hydrogels with biodegradable crosslinking | IDUA, APEH, GUSB | FTO 3442/4885MAPT 3269/4885MEN1 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.